Nerivio

What Nerivio does

Nerivio is a prescription medical device brand operated by Theranica Bio-Electronics Ltd., an Israeli medical device company with US operations through Theranica USA Inc., headquartered in Bridgewater, New Jersey. The company develops and markets the Nerivio family of Remote Electrical Neuromodulation (REN) wearables for acute and preventive migraine treatment in patients aged 8 and older. It serves a horizontal segmentation of migraine sufferers—children, adolescents, adults, veterans, women of childbearing age, patients with comorbidities, and individuals in safety-sensitive occupations—through prescription-only channels that include traditional healthcare providers, a telemedicine partner, a dedicated Veterans Affairs pathway, and international distributors across 8 countries (US, UK, India, Germany, Spain, South Africa, Israel, HK/China).

The core technology is a wearable device applied to the upper arm that delivers electrical stimulation to Aδ and C nerve fibers at 100–120 Hz and 400 μS pulse width, activating the brain's Conditioned Pain Modulation system and triggering descending pain inhibitory pathways that release serotonin and norepinephrine—a mechanism distinct from TENS units that rely on gate-theory pain modulation. The device is controlled via the Nerivio smartphone app (iOS 16+ and Android 11+), which provides machine-learning-driven 24-hour migraine likelihood predictions, treatment tracking, NFC authentication of electrode pads, and Guided Imagery, Education, and Relaxation (GIER) behavioral therapy developed by headache psychologists. Two hardware SKUs are offered: a disposable Nerivio unit providing 18 treatments and a rechargeable Nerivio Infinity model with replaceable electrode pads.

Nerivio operates a prescription hardware-sales model with refill-based revenue mechanics. Retail pricing is up to $1,598 per 18-treatment refill, with a Nerivio Savings Program capping co-insurance at $89 per refill for eligible commercially insured patients; Medicaid and commercial insurance coverage are explicitly supported. Pharmacy fulfillment is handled by ProCare Rx, and the clinical evidence base includes 9 pivotal studies, 25+ peer-reviewed publications, and real-world data from 1.8M+ treatments across 15,000+ patients. FDA clearances include the original De Novo (DEN180059, May 2019), a preventive-treatment clearance (2023), and the expanded pediatric/adolescent indication (K241756, October 2025). The company is privately held with no disclosed funding rounds or external investor information.

Name

Nerivio

Legal name

Theranica Bio-Electronics Ltd.

Website

https://nerivio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Nerivio, a Theranica Bio-Electronics brand, sells FDA-cleared prescription Remote Electrical Neuromodulation wearables for acute and preventive migraine treatment in patients aged 8 and older, distributed via healthcare providers, telemedicine, the VA, and international channels across 8 countries.

Ownership category

akta.pro rank

Product category

Migraine Treatment Device

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)

akta.pro secondary industry

Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ)

Keywords

• Remote electrical neuromodulation
• Migraine treatment device
• Prescription wearable therapy
• Non-invasive neurostimulation
• Digital therapeutics device

Headquarters

HQ city

Bridgewater

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. Device Sales - Nerivio: Prescription-based one-time device purchase model. Nerivio disposable device provides 18 treatments. Starter sets include reusable hardware (armband, charger) plus refill units. Retail price up to $1,598 for 18 treatments.
2. Refill/Replacement Units: Disposable Nerivio devices and Nerivio Infinity electrode pads (18 treatments each) are replaced as consumables through pharmacy fulfillment. Nerivio is prescribed therapy—not a subscription.
3. Nerivio Savings Program: Patient assistance program with co-insurance capped at $89 per refill for eligible commercially insured patients, not available to Medicare, Medicaid, TRICARE or other government healthcare program patients.

Pricing tiers

Distribution channels5 records

Marketing channels7 records

Core offering

Nerivio is a prescription-only Remote Electrical Neuromodulation (REN) wearable device that delivers 45-minute drug-free neurostimulation sessions to the upper arm to prevent and treat migraine in patients ages 8 and older. The product line includes the disposable Nerivio (18 treatments per device) and the rechargeable Nerivio Infinity (replaceable electrode pads with 18 treatments each), both controlled via the Nerivio smartphone app. Devices are prescribed by healthcare providers or through a telemedicine partner, fulfilled by pharmacy partner ProCare Rx, and paid for via insurance (commercial and Medicaid) or the Nerivio Savings Program.

Product overview

Nerivio is a prescription medical device company offering the Nerivio REN (Remote Electrical Neuromodulation) wearable family for drug-free migraine treatment and prevention in patients 8 years and older. The product portfolio consists of two wearable models—Nerivio (disposable, 18 treatments) and Nerivio Infinity (rechargeable with replaceable electrode pads)—both controlled via the Nerivio smartphone app. The app serves as the central platform for treatment management, migraine tracking, ML-powered predictive analytics for 24-hour migraine likelihood, treatment reminders, and access to GIER (Guided Imagery, Education, and Relaxation) behavioral therapy content. Nerivio is prescribed for acute treatment at migraine onset and/or preventive treatment every other day, offering dual-use therapy without systemic side effects.

Differentiator

Problem solved

Functional benefit

Products and services

• Nerivio (disposable wearable) A prescription-required, single-use Remote Electrical Neuromodulation (REN) wearable device providing 18 treatments of 45 minutes each, controlled via the Nerivio smartphone app, indicated for acute and preventive migraine treatment in patients ages 8 and older.
• Nerivio Infinity (rechargeable wearable) A rechargeable, durable Remote Electrical Neuromodulation (REN) wearable with replaceable electrode pads (each providing 18 treatments), managed through the Nerivio app with NFC authentication for electrode pairing, indicated for acute and preventive migraine treatment in patients ages 8 and older.

Quantifiable outcome

• 66.7% of patients achieved pain relief at 2 hours post-treatment (Yarnitsky et al. 2019)
• +9 more outcomes

Named customers8 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

One partnership is on record.

• ProCare RxcoreChannel Partner/ Reseller/ DistributorPrimary pharmacy fulfillment partner for Nerivio prescriptions. After healthcare provider prescribes Nerivio, ProCare Rx contacts patients for insurance and payment information and delivers devices directly to patient doorstep. Handles both initial prescriptions and refills.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• gammaCore (electroCore): gammaCore is a non-invasive vagus nerve stimulation (nVNS) device FDA-cleared for migraine and cluster headache; it is the closest analog to Nerivio in the prescription neuromodulation migraine category with overlapping prescribers and payer positioning.
• eNeura (SpringTMS): eNeura's SpringTMS is a single-pulse transcranial magnetic stimulation device FDA-cleared for acute and preventive migraine, making it a direct neuromodulation peer to Nerivio within the prescription, non-pharmacologic migraine category.
• Relivion (Neurolief): Relivion is an external, multi-channel trigeminal and occipital nerve stimulation headset for acute migraine, directly competing with Nerivio's non-invasive, app-controlled neurostimulation approach for the same patient population.
• Cefaly: Cefaly is a direct competitor offering an external TENS-based trigeminal nerve stimulation device (Cefaly Connected) for migraine prevention and acute treatment, overlapping with Nerivio on indication, prescription channel, and patient demographic.

Broad incumbents

• AbbVie (Botox, Ubrelvy): AbbVie markets Botox for chronic migraine and Ubrelvy (ubrogepant) for acute migraine, providing both preventive and acute pharmacologic alternatives that compete with Nerivio's drug-free positioning across the migraine treatment continuum.
• Lundbeck (Vyepti): Lundbeck's Vyepti (eptinezumab) is an IV-administered CGRP monoclonal antibody for migraine prevention, a larger-pharma preventive option that competes for the same specialty neurology prescribing channel Nerivio targets.
• Teva Pharmaceutical (Ajovy): Teva markets Ajovy (fremanezumab), a CGRP monoclonal antibody for migraine prevention, representing another injectable preventive pharmacologic option that competes with Nerivio's non-pharmacologic preventive claim.
• Pfizer (Nurtec ODT): Pfizer markets Nurtec ODT, a leading oral CGRP receptor antagonist gepant for acute and preventive migraine; it competes with Nerivio for the same prescriber and patient mindshare within broader migraine therapy.
• Eli Lilly (Emgality, Reyvow): Eli Lilly markets Emgality (galcanezumab), a CGRP monoclonal antibody for migraine prevention, and Reyvow (lasmiditan), an acute serotonin receptor agonist, both directly competitive alternatives to Nerivio within migraine management.

Emerging players

• Salvia Bioelectronics: Salvia is an early-stage Dutch neurostim developer working on a thin, foil-like active implantable device targeting chronic headache disorders, including cluster headache; relevant as a forward-looking neurostimulation peer entering Nerivio's broader headache adjacency.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• TikToktiktok.com/@nerivio
• Xx.com/theranica
• Facebookfacebook.com/NerivioXTheranica
• LinkedInlinkedin.com/company/nerivio

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nerivio